Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.